大うつ病性障害：グローバル治療薬予測と市場分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 8
1.1 List of Tables15
1.2 List of Figures 21
2 Introduction 23
2.1 Catalyst 23
2.2 Related Reports 23
2.3 Upcoming Related Reports 23
3 Disease Overview 24
3.1 Etiology and Pathophysiology 24
3.1.1 Etiology 24
3.1.2 Pathophysiology 24
3.2 Classification 26
3.3 Symptoms and Subtypes of Major Depressive Disorder 28
3.4 Prognosis 29
3.5 Quality of Life 29
4 Epidemiology 30
4.1 Risk Factors and Comorbidities 30
4.1.1 A Family History of MDD Increases the Risk for MDD by Almost 14 Times 30
4.1.2 Substance Abuse and Lifetime Anxiety Disorders are Highly Prevalent in MDD Patients 31
4.2 Global and Historical Trends 32
4.3 Forecast Methodology 35
4.3.1 Sources Used 37
4.3.2 Forecast Assumptions and Methods 41
4.3.3 Sources Not Used 43
4.4 Epidemiological Forecast for MDD (2013-2023) 45
4.4.1 Total Prevalent Cases of MDD 45
4.4.2 Age-Specific Total Prevalent Cases of MDD 47
4.4.3 Sex-Specific Total Prevalent Cases of MDD 48
4.4.4 Age-Standardized Total Prevalence of MDD 50
4.5 Discussion 51
4.5.1 Epidemiological Forecast Insight 51
4.5.2 Limitations of the Analysis 52
4.5.3 Strengths of the Analysis 53
5 Disease Management 54
5.1 Diagnosis and Treatment Overview 54
5.1.1 Diagnosis 54
5.1.2 Treatment Guidelines and Leading Prescribed Drugs 55
5.1.3 Clinical Practice 58
5.2 US 62
5.3 France 65
5.4 Germany 67
5.5 Italy 69
5.6 Spain 72
5.7 UK 74
5.8 Japan 76
5.9 Australia 78
6 Competitive Assessment 80
6.1 Overview 80
6.2 Product Profiles: Major Brands, Selective Serotonin Reuptake Inhibitors 82
6.2.1 Lexapro (Escitalopram) 82
6.2.2 Viibryd (Vilazodone) 86
6.2.3 Other Selective Serotonin Reuptake Inhibitors 91
6.3 Product Profiles: Major Brands, Serotonin-Norepinephrine Reuptake Inhibitors 95
6.3.1 Effexor (Venlafaxine) 95
6.3.2 Cymbalta (Duloxetine) 100
6.3.3 Pristiq (Desvenlafaxine) 104
6.3.4 Fetzima (Levomilnacipran) 109
6.3.5 Savella (Milnacipran) 114
6.4 Product Profiles: Major Brands, Other Antidepressants 117
6.4.1 Norepinephrine-Dopamine Reuptake Inhibitors 117
6.4.2 Noradrenaline and Specific Serotonergic Antidepressants 122
6.4.3 Monoamine Oxidase Inhibitors 127
6.4.4 Tricyclic Antidepressants 130
6.4.5 Brintellix (Vortioxetine) 133
6.5 Product Profiles: Major Brands, Antipsychotics 140
6.5.1 Abilify (Aripiprazole) 140
6.5.2 Seroquel XR (Quetiapine) 145
6.6 Other Therapeutic Classes 150
7 Unmet Needs and Opportunities 151
7.1 Overview 151
7.2 More Effective Pharmacotherapies 152
7.2.1 Unmet Needs 152
7.2.2 Gap Analysis 153
7.2.3 Opportunities 154
7.3 More Favorable Side Effect Profiles 154
7.3.1 Unmet Needs 154
7.3.2 Gap Analysis 155
7.3.3 Opportunities 155
7.4 Rapid Onset of Antidepressant Effects 156
7.4.1 Unmet Needs 156
7.4.2 Gap Analysis 156
7.4.3 Opportunities 156
7.5 Personalized Treatment Approach 157
7.5.1 Unmet Needs 157
7.5.2 Gap Analysis 158
7.5.3 Opportunities 158
8 Pipeline Assessment 159
8.1 Overview 159
8.2 Clinical Trial Mapping 159
8.2.1 Clinical Trials by Class of Therapy 159
8.3 Promising Drugs in Clinical Development 160
8.3.1 Brexpiprazole (OPC-34712) 163
8.3.2 Cariprazine (RGH-188) 170
8.3.3 ALKS-5461 176
8.3.4 Amitifadine (EB-1010) 183
8.3.5 GLYX-13 189
8.3.6 Tedatioxetine (Lu AA24530) 194
8.3.7 ETS6103 199
8.4 Other Drugs in Development 204
9 Current and Future Players 206
9.1 Overview 206
9.2 Trends in Corporate Strategy 209
9.3 Company Profiles 210
9.3.1 Lundbeck 210
9.3.2 Forest Laboratories (Actavis) 214
9.3.3 Eli Lilly 217
9.3.4 Pfizer 218
9.3.5 Otsuka Pharmaceutical 220
9.3.6 AstraZeneca 222
9.3.7 Takeda Pharmaceutical 224
9.3.8 Alkermes 226
9.3.9 Euthymics Bioscience 228
9.3.10 Naurex 230
9.3.11 e-Therapeutics 232
10 Market Outlook 235
10.1 Global 235
10.1.1 Forecast 235
10.1.2 Drivers and Barriers – Global Issues 239
10.2 US 241
10.2.1 Forecast 241
10.2.2 Key Events 245
10.2.3 Drivers and Barriers 245
10.3 France 248
10.3.1 Forecast 248
10.3.2 Key Events 251
10.3.3 Drivers and Barriers 251
10.4 Germany 253
10.4.1 Forecast 253
10.4.2 Key Events 257
10.4.3 Drivers and Barriers 257
10.5 Italy 259
10.5.1 Forecast 259
10.5.2 Key Events 263
10.5.3 Drivers and Barriers 263
10.6 Spain 265
10.6.1 Forecast 265
10.6.2 Key Events 269
10.6.3 Drivers and Barriers 269
10.7 UK 271
10.7.1 Forecast 271
10.7.2 Key Events 275
10.7.3 Drivers and Barriers 275
10.8 Japan 277
10.8.1 Forecast 277
10.8.2 Key Events 281
10.8.3 Drivers and Barriers 281
10.9 Australia 284
10.9.1 Forecast 284
10.9.2 Key Events 287
10.9.3 Drivers and Barriers 287
11 Appendix 290
11.1 Bibliography 290
11.2 Abbreviations 300
11.3 Methodology 305
11.4 Forecasting Methodology 305
11.4.1 Diagnosed MDD Patients 305
11.4.2 Percent of Drug-Treated Patients 305
11.4.3 Drugs Included in Each Therapeutic Class 306
11.4.4 Launch and Patent Expiry Dates 306
11.4.5 General Pricing Assumptions 307
11.4.6 Individual Drug Assumptions 308
11.4.7 Generic Erosion 314
11.4.8 Pricing of Pipeline Agents 314
11.5 Physicians and Specialists Included in this Study 316
11.6 About the Authors 318
11.6.1 Analyst 318
11.6.2 Therapy Area Directors 318
11.6.3 Epidemiologist 319
11.6.4 Global Head of Healthcare 320
11.7 About GlobalData 321
11.8 Disclaimer 321